SOPHiA GENETICS SA·4

Mar 20, 4:01 PM ET

Muken Ross 4

4 · SOPHiA GENETICS SA · Filed Mar 20, 2026

Research Summary

AI-generated summary of this filing

Updated

SOPHiA GENETICS (SOPH) President Muken Ross Sells 1,183 Shares

What Happened Muken Ross, President of SOPHiA GENETICS SA (SOPH), sold 1,183 shares on March 19, 2026, for a reported weighted-average price of $4.79 per share, totaling $5,671 (disposition). This was a sale (not a purchase) and appears to be a routine, tax-related disposition rather than a discretionary trade.

Key Details

  • Transaction date: 2026-03-19; Filing date: 2026-03-20 (filed timely).
  • Shares sold: 1,183; Weighted-average price reported: $4.79; Total proceeds: $5,671.
  • Price range: shares were sold in multiple trades at prices between $4.69 and $4.87 (per footnote).
  • Reason/footnotes: Sale was to satisfy tax obligations tied to RSU vesting on 2026-03-18 and was effected under a pre-established Rule 10b5-1 trading plan (non-discretionary).
  • Shares owned after the transaction: not disclosed in the provided filing excerpt.

Context

  • This sale was tax withholding related to restricted stock unit vesting and executed under a 10b5-1 plan—common, routine insider transactions that do not necessarily signal a change in the insider's view on the company.
  • The dollar amount is small relative to typical insider trades; purchases (not present here) are generally more informative about insider sentiment.

Insider Transaction Report

Form 4
Period: 2026-03-19
Muken Ross
President
Transactions
  • Sale

    Ordinary Shares

    [F1][F2]
    2026-03-19$4.79/sh1,183$5,671271,910 total
Footnotes (2)
  • [F1]Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 18, 2026. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
  • [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.69 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Elimara Brunetto as Attorney-in-fact for Ross Muken|2026-03-20

Documents

1 file
  • 4
    wk-form4_1774036866.xmlPrimary

    FORM 4